Back to Search
Start Over
Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.
- Source :
-
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Dec 07; Vol. 12, pp. 789957. Date of Electronic Publication: 2021 Dec 07 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Drugs useful in prevention/treatment of obesity could improve health. Cholecystokinin (CCK) is a key regulator of appetite, working through the type 1 CCK receptor (CCK1R); however, full agonists have not stimulated more weight loss than dieting. We proposed an alternate strategy to target this receptor, while reducing likelihood of side effects and/or toxicity. Positive allosteric modulators (PAMs) with minimal intrinsic agonist activity would enhance CCK action, while maintaining spatial and temporal characteristics of physiologic signaling. This could correct abnormal stimulus-activity coupling observed in a high-cholesterol environment observed in obesity. We utilized high-throughput screening to identify a molecule with this pharmacological profile and studied its basis of action. Compound 1 was a weak partial agonist, with PAM activity to enhance CCK action at CCK1R, but not CCK2R, maintained in both normal and high cholesterol. Compound 1 (10 µM) did not exhibit agonist activity or stimulate internalization of CCK1R. It enhanced CCK activity by slowing the off-rate of bound hormone, increasing its binding affinity. Computational docking of Compound 1 to CCK1R yielded plausible poses. A radioiodinatable photolabile analogue retained Compound 1 pharmacology and covalently labeled CCK1R Thr <superscript>211</superscript> , consistent with one proposed pose. Our study identifies a novel, selective, CCK1R PAM that binds to the receptor to enhance action of CCK-8 and CCK-58 in both normal and disease-mimicking high-cholesterol environments. This facilitates the development of compounds that target the physiologic spatial and temporal engagement of CCK1R by CCK that underpins its critical role in metabolic regulation.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Harikumar, Coudrat, Desai, Dong, Dengler, Furness, Christopoulos, Wootten, Sergienko, Sexton and Miller.)
- Subjects :
- Allosteric Regulation drug effects
Allosteric Regulation physiology
Animals
CHO Cells
Cholecystokinin chemistry
Cricetinae
Cricetulus
Dose-Response Relationship, Drug
Humans
Hypercholesterolemia drug therapy
Hypercholesterolemia metabolism
Macaca fascicularis
Mice
Rats
Chemokines, CC agonists
Chemokines, CC metabolism
Cholecystokinin metabolism
Cholecystokinin pharmacology
Cholesterol metabolism
Drug Discovery methods
Subjects
Details
- Language :
- English
- ISSN :
- 1664-2392
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 34950108
- Full Text :
- https://doi.org/10.3389/fendo.2021.789957